Abstract
A total of 23 advanced gastric cancer patients older than 65 years received 500 mg/m2 5-fluorouracil i.v. on days 2–4, 120 mg/m2 vepesid i.v. on days 2–4, 150 mg/m2 6S-leucovorin on days 2–4, and 5 MU/m2 interferon alpha-2b on days 1–5, with cycles being repeated every 3 weeks. Toxicity was severe at an interferon (IFN) dose of 5 MU/m2; only one patient tolerated this dose. In 18 patients an IFN dose of 3 MU/m2 and in 3 other patients a dose of 4 MU/m2 could be given withoutproducing toxicity. At an IFN dose of 5 MU/m2 the most common toxicities encountered were stomatitis (grade 4 in 1 patient and grade 3 in 12 patients), leukopenia (grade 4 in 1 patient and grade 3 in 5 patients), and thrombocytopenia (grade 3 in 3 patients). Two patients achieved a complete response and eight showed a partial response, resulting in an overall response rate of 45% [95% confidence interval (CI), 25%–64%]. The median survival was 7 months for all patients and 9 months for responding patients. In conclusion, without substantially increasing the toxicity, IFN can be added to the etoposide/leucovorin/5-fluorouracil combination, at a dose of 3 MU/m2. To verify the possible enhancement by IFN of the activity of this combination, a randomized trial is under way.
Similar content being viewed by others
References
Wilke H, Preusser P, Stahl M, Fink U, Schmoll HJ, Achterrath W, Lenaz I, Meyer HJ, Wegener G, Poliwoda H (1989) Leucovorin/5-fluorouracil alone or in combination with other cytostatic drugs in the treatment of advanced gastric carcinoma. Pinedo HM, Rustum YM (eds) Leucovorin modulation of fluoropyrimidines: a new frontier in cancer chemotherapy. Royal Society of Medicine Services, International Congress and Symposium, London, p 87
Dorr RT, Fritz WL (1980) Drug data sheets: 5-fluorouracil. In: Dorr RT, Fritz WL (eds) Cancer chemotherapy handbook. Elsevier, New York, p 435
O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide. N Engl J Med 312: 692
Wilke H, Preusser P, Fink U, Achterraht W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, Konne-Wompner CH, Harstrick A, Schmoll HJ (1990) New developments in the treatment of gastric carcinoma. Semin Oncol 17 [Suppl 2]: 61
Wilke H, Preusser P, Stahl M, Harstick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 29: 83
Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473
Von Hoff DD (1991) In vitro data supporting interferon plus cytotoxic agent combinations. Semin Oncol 18 [Suppl 7]: 58
Miller AB, Hoodgstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207
Dorr RT, Fritz WL (1980) Toxicity of VP16-213. In: Dorr RT, Fritz WL (eds) Cancer chemotherapy handbook. Elsevier, New York, p 418
Arbuck SG, Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of fluorouracil and high-dose intravenous leucovorin in gastric carcinoma. J Clin Oncol 5: 1150
Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, Sorensen JM, Dartor O, Kramer BS, Goldstein LJ, Gay LM, Caubo KM, Goldspiel B, Allegra CJ (1991) A pilot study of interferon alpha 2a in combination with fluorouracil plus highdose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 9: 1811
Lin SL, Kikuchi T, Pledger WJ, Tamm I (1986) Interferon inhibits the establishment of competence in GO/S phase transition. Science 233: 356
Wadler S, Goldman M, Lyver A, Wiernik PH (1990) Phase I trial of 5-fluorouracil and recombinant alpha 2a interferon in patients with advanced colorectal carcinoma. Cancer Res 50: 2056
Modiano M, Taylor C, Brooks R, Wiggins C, Power J, Alberts D (1993) Etoposide (E), leucovorin (L), 5-fluorouracil (F) and interferon alpha 2a (I) (ELFI) is an active treatment for high-risk or advanced pancreatic or gastric adenocarcinoma. Proc Am Soc Clin Oncol 12: 203
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cascinu, S., Fedeli, A. & Catalano, G. Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. Cancer Chemother. Pharmacol. 34, 72–74 (1994). https://doi.org/10.1007/BF00686115
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686115